Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. - Langley, Richard G. B.; Reich, Kristian; Strand, Vibeke; Feldman, Steven R.; Paul, Carle; Gordon, Kenneth; Warren, Richard B.; Toth, Darryl; Nikaï, Enkeleida; Zhu, Baojin; Goldblum, Orin; Edson-Heredia, Emily; et al. (Quality of Life Research, 2020)